. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2017 Jun 1;75(Suppl 2):S149–S155. doi: 10.1097/QAI.0000000000001368

Table 2. Virologic and Resistance outcomes at 6 months according to study arm.

Outcome	Arm 1	Arm 2	Arm 3	p-value
Number enrolled (N)	447	428	394	N/A
Retained at 6 mo (n/N, %)	312 (70%)	323 (75%)	315 (80%)
Duration of ART use at time of sampling (median, IQR)	263(232-294)	252 (228-292)	267(239-302)	0.326
HIVRNA collected (n/N, %)	247 (55%)	312 (72%)	274 (70%)	<0.001
< 1000 Copies/ml (n, %)	208 (84%)	254(81 %)	237 (87%)	0.20
1000< 5000 copies/ml (n, %)	24 (10%)	26 (8 %)	21 (8 %)
>5000 copies/ml (n, %)	15 (6 %)	32 (10%)	16 (6%)
Log₁₀ HIVRNA (median, IQR)	3.4 (3.2-4.4)	3.9 (3.3-4.6)	3.5 (3.3-4.6)	0.723
Eligible for Resistance testing	39	58	37	N/A
Conducted Resistance (n, %)	34 (87%)	56 (97%)	27 (73%)	0.003
Failed to Amplify (n, %)	20 (59%)	27 (48%)	15 (56%)	0.226
Amplified (n, %)	14 (41%)	29 (52%)	12 (44%)	0.226
“Any Resistance”, (n, %)	3 (8%)	9(24%)	7 (58%)	0.198
NRTI resistance	1 (7%)	1 (3%)	3 (25%)	0.130
NNRTI resistance	3 (8%)	9 (24%)	7 (58%)	0.198